ORKA · Oruka Therapeutics, Inc. · Stock research

The narrative is maturing. The August impulse is dated and now two weeks old: the 2026-08-10 Q2 update that attached calendar dates to every pending readout, the 2026-08-11 Guggenheim $200 and BTIG $151 reiterations, and the push to a $113.08 52-week high. Since then the tape has drifted rather than extended — the 2026-08-21 close of $107.96 sits 4.5% under that high with RSI(14) at 70.3 against 80.2 on 08-14 — while the newest corporate action is a supply registration (2026-08-21 S-3 for up to $1B, carrying a $500M at-the-market program per the filing record) and three insider Form 4 sales printed between 08-14 and 08-17. Participation is still widening — RTW filed a 5.2% 13G and Capital World a 5.6% 13G on 08-12/08-14 — so this is well-known-and-still-working, not late-cycle exhaustion.

ORKA — Oruka Therapeutics, Inc.

Current Thesis

The August frame holds: on 2026-08-10 the company converted an undated binary into a dated one — EVERLAST-A Week 28 for all participants at the end of 3Q 2026, EVERLAST-A 52-week data in December 2026, EVERLAST-B Week 16 pulled out of 2027 into 4Q 2026, and an ORKA-001 Phase 3 program guided to begin in 1H 2027. That has not changed in the six sessions since the last note.

What changed is the supply side. On 2026-08-21 Oruka filed a shelf registration for up to $1B of common stock, preferred stock, depositary shares and warrants, which the filing record describes as including a $500M at-the-market sales agreement with TD Cowen. This lands eleven days after management stated that $1.1B of cash, equivalents and marketable securities at 2026-06-30 funds operations through an anticipated ORKA-001 BLA filing. An equal-size $1B shelf was filed on 2026-04-02, when the last reported sale price was $50.43 (2026-04-01); the new one arrives with the last close at $107.96. Registering capacity is not selling stock, but an ATM is a mechanism that converts strength into shares without a marketed deal or a press release, and it now exists ahead of the two largest data events.

The narrative leg being bought is unchanged in substance: a long-acting IL-23 antibody with a ~100-day half-life whose Week 16 numbers (63.5% PASI 100) must now demonstrate durability at Week 28 and be replicated in a larger trial, inside an M&A tape reset by AbbVie's $135.11/share, $10.9B acquisition of Apogee on 2026-06-22. Nothing about the maintenance question resolves before the end of September.

Bullish and bearish views on Oruka Therapeutics, Inc.

The model's bull view on Oruka Therapeutics, Inc. (ORKA), in brief: Dated catalyst density, confirmed 2026-08-10: Week 28 all-participant data end of 3Q 2026; 52-week data December 2026; EVERLAST-B Week 16 in 4Q 2026 (fully enrolled ahead of schedule); ORKA-004 TL1A clinical entry Q4 2026; ORCA-SURGE Week 16 in Q1 2027; ORKA-001 Phase 3 start… The bear view: A $500M ATM now sits over the tape. The 2026-08-21 registration was filed into a price near the 52-week high by a company that had just guided its cash as sufficient through a BLA. Shares issued under an ATM appear after the fact in a 424B5 or the next 10-Q, so the market learns… Both cases follow in full.

Bull Case

• Dated catalyst density, confirmed 2026-08-10: Week 28 all-participant data end of 3Q 2026; 52-week data December 2026; EVERLAST-B Week 16 in 4Q 2026 (fully enrolled ahead of schedule); ORKA-004 TL1A clinical entry Q4 2026; ORCA-SURGE Week 16 in Q1 2027; ORKA-001 Phase 3 start guided to 1H 2027.
• The efficacy bar is already cleared (2026-04-27): 40 of 63 EVERLAST-A participants (63.5%) at PASI 100, 83% PASI 90, 84% IGA 0/1 at Week 16. Week 28 asks whether that holds and whether Week-16 sub-PASI-100 responders deepen — a maintenance question on top of a printed result.
• Balance sheet covers the decision points: $1.1B in cash, equivalents and marketable securities at 2026-06-30, guided sufficient through an anticipated ORKA-001 BLA filing. Six-month net loss of $73M per the 2026-08-10 10-Q against that cash line leaves no financing forcing function before the readouts.
• Institutional register broadened in August: Venrock healthcare funds 7.4% (4.56M shares, 13G/A 08-14), Capital World Investors 5.6% (3.40M, 13G 08-12), RTW Investments 5.2% (3.14M, 13G 08-14), Viking Global 2.5% (1.50M, 13G/A 08-14).
• Sell-side range re-set upward: Guggenheim Buy/$200 and BTIG Buy/$151 on 2026-08-11, H.C. Wainwright Buy/$120 on 2026-08-03. The $200 print sits above the $160 top of the range that framed the name in July.
• The comparable is asset-specific: Apogee and Oruka were both seeded by Paragon Therapeutics and both pursue extended-half-life biologics that collapse injection frequency in inflammatory skin disease. AbbVie's 2026-06-22 deal put a number on that structure.

Bear Case

• A $500M ATM now sits over the tape. The 2026-08-21 registration was filed into a price near the 52-week high by a company that had just guided its cash as sufficient through a BLA. Shares issued under an ATM appear after the fact in a 424B5 or the next 10-Q, so the market learns about the dilution on a lag.
• Plan-driven sales are routine; the dates cluster at the high regardless.
• No base between the breakout and the high. The August leg cleared the $97.78 prior 52-week high without retesting it and topped at $113.08. Everything between those two prices was traded through once, in one direction, inside about three weeks.
• The Q2 print itself was not the driver. EPS of $(0.55) missed the $(0.51) consensus, with R&D at $43.3M against $24.1M a year earlier and net loss $41.2M against $24.6M. Expense growth is the visible business fact; the re-rating rests entirely on guidance dates.
• The 3Q guidance window closes fast. "End of 3Q 2026" means 2026-09-30. If that date passes without data and without a fresh 8-K naming a new one, the name reverts to the undated-binary condition it carried through June, at roughly double June's price.
• Week 28 is genuinely two-sided. A maintenance readout below the 63.5% Week 16 PASI 100 rate, or one delivered without a clear maintenance-of-response statement, undercuts the 6–12-month dosing claim that separates ORKA-001 from quarterly-dosed IL-23 incumbents.

Setup & Price Structure

Reference points, from split/dividend-adjusted daily bars: the 2026-08-21 close was $107.96; the 52-week high is $113.08, so price is 4.5% below it; the three-month price change is +78.1%; RSI(14) is 70.3, cooled from 80.2 on 2026-08-14 when the close was $111.04.

The structure below is a stack of prints rather than a consolidation. $97.78 is the pre-August 52-week high the breakout cleared. $92.70 is the 2026-07-17 close that marked the post-block recovery. $84.43 is the July 1 Fairmount block price where $300M of stock was absorbed. $72.50 is the May follow-on price. Losing $97.78 on a closing look would put price back inside the July range with no intervening shelf built during the August advance.

Crowding observables, stated as observables: four sell-side reiterations inside nine sessions (08-03 through 08-11); four 13G/13G-A filings between 08-12 and 08-14, which is the 45-day post-quarter deadline rather than evidence of fresh August buying; three insider sales in four sessions; a $1B shelf with an ATM component filed 08-21; and short interest last read near 19.85% of float — a figure worth re-checking against the exchange bi-monthly file, since aggregators printed an implausible zero-share reading for ORKA in August 2026. High short interest cuts both ways here: it amplifies a positive Week 28 print and it is also the fuel that has already been partly spent during a +78.1% three-month move.

Catalyst Calendar (next 30 days)

• No company-confirmed date falls between 2026-08-23 and 2026-09-22. The guided window for the next binary closes at quarter-end, and a release can arrive on any morning inside it by press release and 8-K without advance notice.
• ~2026-09-30 (est.) — EVERLAST-A Week 28 data, all participants (guided "end of 3Q 2026" on 2026-08-10). First six-month maintenance look at ORKA-001.
• ~2026-11-10 (est.) — Q3 2026 results and corporate update. First scheduled disclosure of any ATM usage under the 2026-08-21 shelf, plus confirmation or revision of the December and 4Q guidance.
• ~2026-11-30 (est.) — EVERLAST-B Phase 2b Week 16 data (guided 4Q 2026).
• ~2026-12-15 (est.) — EVERLAST-A 52-week data, all participants (guided December 2026).
• ~2026-12-31 (est.) — ORKA-004 (TL1A antibody) clinical entry, guided Q4 2026.

What Would Change Our Mind

The structural break is the August breakout shelf. The advance from the 2026-07-17 close of $92.70 to the $113.08 high was built on clearing $97.78, and nothing was consolidated on the way up; a daily close below $97.78 hands that level back and returns price to the July range where the Fairmount block at $84.43 was digested. That is the gradeable line.

Three non-price conditions would change the read independently. First, 2026-09-30 passing with no EVERLAST-A Week 28 release and no 8-K or advisory naming a new date — the dated-catalyst premium established on 2026-08-10 would be the thing that expired, not the science. Second, a 424B5 pricing an offering below the prevailing close, or a 10-Q disclosing meaningful ATM issuance under the 2026-08-21 shelf, which converts the registration from optionality into realized supply. Third, a Week 28 PASI 100 rate materially under the 63.5% Week 16 figure, which attacks the durability claim itself rather than the tape.

On the other side, the label here moves back to accelerating if Week 28 prints at or above the Week 16 response with an explicit maintenance statement and price holds above the $113.08 high on a closing look — that combination would put a second confirmatory readout (EVERLAST-B, 4Q) into a market that has already accepted the durability premise.

Correlation Notes

• Paragon-seeded cohort: the AbbVie–Apogee transaction (2026-06-22, $135.11/share, $10.9B) is the reference deal for the extended-half-life I&I structure. With Apogee absorbed, the surviving listed comparables in that family carry the read-across, and any second long-acting I&I acquisition would reprice the group rather than one name.
• IL-23 incumbency: the economic case is displacement of quarterly-dosed IL-23 biologics (AbbVie's Skyrizi, J&J's Tremfya). Competitor data showing equal efficacy with easier dosing narrows the differentiation that carries the valuation; incumbent commercial commentary at Q3 prints is where that pressure would first be visible.
• Biotech beta and rates: a pre-revenue, cash-rich clinical name with a duration-heavy payoff trades with XBI and with front-end rates. A broad biotech drawdown can take out the $97.78 level without any company-specific news, which is why the invalidation is stated as a price condition and the data question is stated separately.
• Short-interest mechanics: with float short last read near 19.85%, single-day moves in either direction around the Week 28 release should be expected to overshoot the information content of the release itself.